Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31.

@article{Tanchiu2005AssessmentOC,
  title={Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31.},
  author={Elizabeth Tan-chiu and Greg Yothers and Edward H. Romond and Charles Edward Geyer and Michael S. Ewer and Deborah L. Keefe and Richard P. Shannon and Sandra M Swain and Ann Brown and Louis Fehrenbacher and Victor G. Vogel and Thomas Seay and Priya Rastogi and Eleftherios P Mamounas and Norman Wolmark and John Bryant},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2005},
  volume={23 31},
  pages={7811-9}
}
PURPOSE Trastuzumab is effective in treating human epidermal growth factor receptor 2 (HER2) -positive breast cancer, but it increases frequency of cardiac dysfunction (CD) when used with or after anthracyclines. PATIENTS AND METHODS National Surgical Adjuvant Breast and Bowel Project trial B-31 compared doxorubicin and cyclophosphamide (AC) followed by paclitaxel with AC followed by paclitaxel plus 52 weeks of trastuzumab beginning concurrently with paclitaxel in patients with node-positive… CONTINUE READING
Highly Influential
This paper has highly influenced 12 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS

Citations

Publications citing this paper.
Showing 1-10 of 274 extracted citations

Similar Papers

Loading similar papers…